Since the first description of subcutaneous
protein C concentrate as treatment for severe
protein C deficiency in 1996, further cases have been reported but there is no uniform approach to this form of treatment. In order to assess the safety and effectiveness of subcutaneous
protein C concentrate and suggest recommendations for future use, patients who had received subcutaneous
protein C concentrate were identified from the literature, by contacting the manufacturers and by personal communication. Treatment details were available from 14 cases. Apart from one case where the infusion interval was inadvertently increased, no thrombotic events occurred even when doses were subsequently reduced. Initially, a trough
protein C level of >0·25 iu/ml should be aimed for. Subsequently, a smaller dose of subcutaneous
protein C concentrate, especially if taken with an oral
anticoagulant, may be protective maintenance treatment. The treatment was well tolerated with few side effects. Subcutaneous
protein C concentrate on its own or combined with an oral
anticoagulant appears to be safe and effective as maintenance treatment of severe
protein C deficiency. A major advantage is the avoidance of central venous access devices. The incidence of neurodevelopmental handicap was high with
blindness affecting the majority of patients.